Zydus Lifesciences to Acquire Majority Stake in Amplitude Surgical

In a strategic move to bolster its presence in the global medtech sector, Zydus Lifesciences has announced its intention to acquire an 85.6% stake in France-based Amplitude Surgical. This acquisition, valued at Euro 256.8 million, marks a significant step forward in Zydus's ambition to become a leading player in the medical technology space.

Strategic Implications of the Acquisition

The deal, which involves negotiations with PAI Partners and Amplitude Surgical’s management, as well as two minority shareholders, is set at €6.25 per share. This price represents a substantial premium over recent trading prices, underscoring the value Zydus sees in Amplitude Surgical's innovative orthopaedic technologies and its potential for growth in the medtech sector.

Future Plans and Vision

Following the acquisition, Zydus Lifesciences plans to initiate a tender offer to acquire the remaining shares, aiming for a full takeover and subsequent delisting of Amplitude Surgical. Sharvil Patel, managing director of Zydus Lifesciences, emphasized the strategic fit of this acquisition, highlighting the company's commitment to advancing its global medtech ambitions through quality excellence, R&D investments, and manufacturing expertise.